Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Exec appointment
confidence 75%
filed 2026-07-13
Item 5.02
The filing discloses both the resignation of Edward M. Weil, Jr. as Chairman and director (effective July 9, 2026) and the appointment of Nicholas S. Schorsch, Jr. as Class III director and Chairman on July 10, 2026. While both events occurred, the principal action disclosed is the appointment of a new Chairman to fill the vacancy, making exec_appointment the most salient classification. Schorsch, Jr. was already serving as CEO since March 2025 and brings substantial real-estate and capital markets experience, making this a material leadership transition.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-13
Item 5.02
The filing discloses the appointment of Barend (Barrie) J. van der Merwe, the current Chief Financial Officer, to the position of Chief Executive Officer effective August 1, 2026, along with his election as Managing Director of the Board. While the section also covers the departure of the interim CEO (Spindler) and appointment of an interim CFO (Deoji), the principal disclosed action centers on the appointment of a new CEO—a material executive leadership change. The detailed compensation terms and board expansion to accommodate this appointment further underscore the materiality of this executive appointment event.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 85%
filed 2026-07-13
EX-99.1
The press release announces the appointment of Dr. Jeff Millard as Executive Vice President, Technical Operations, effective July 13, 2026, and the promotion of Dr. Alex Therien to Executive Vice President, Research & Development. While the release also discloses Amanda Malone's departure as Chief Scientific and Operating Officer, the principal disclosed action is the addition of experienced executive leadership to support the company's transition to late-stage development ahead of the Q4 2026 RESOLVE trial interim release. This is material to investors assessing management capability during a critical growth phase.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-13
Item 5.02
Nickolas Stavropoulos was appointed to ONE Gas's Board of Directors on July 13, 2026, expanding the board from eight to nine members. He was assigned to three board committees (Audit, Corporate Governance, and Executive Compensation) and brings 40+ years of energy industry experience, including prior roles as COO of PG&E and National Grid.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-13
Item 5.02
The Board elected Ms. Ekta Singh-Bushell as a director effective August 1, 2026, and appointed her to the Audit Committee. This is a clear executive appointment to the Board of Directors, the principal disclosed action. While the Item 5.02(d) section also mentions compensatory arrangements (customary non-employee director compensation), the core event is the appointment itself, which is material to investors as it affects board composition and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-13
Item 5.02
The filing discloses the appointment of John Mitchell to Energy Recovery's Board of Directors on July 9, 2026, expanding the board to six directors. This is a clear executive appointment under Item 5.02, with detailed biographical information about Mitchell's extensive leadership experience at TE Connectivity and other technology-driven companies. Board appointments are material governance events affecting investor assessment of the company's leadership and strategic direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-13
Item 5.02
The disclosure centers on the Board's appointment of Alexis N. Tirrito as interim CFO effective July 7, 2026, following Raymond S. Frech's resignation as CFO on the same day. While both a departure and appointment occur, the principal disclosed action is Tirrito's assumption of the CFO role with associated compensation adjustments ($240,000 base salary and 20% target bonus). This is material as it involves a change in principal financial officer and principal accounting officer positions at the company.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-13
The filing discloses the appointment of Brynner Chiam as Interim Co-Chief Executive Officer effective July 10, 2026, alongside existing Co-CEO Shang Ju Lin. This is a material executive appointment to a senior leadership role. Mr. Chiam, who has served as CFO and director since August 2025, will continue in those roles while assuming the interim co-CEO position, representing a significant change in the Company's leadership structure during a stated "transitional period."
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-13
Item 5.02
The Trade Desk appointed Penry Price to its board of directors effective July 9, 2026, as a Class II director with committee assignments (Audit Committee member and Compensation Committee chair). While the disclosure includes compensatory details (annual cash of $112,500 plus equity grants valued at $290,000 initial and $290,000 annual), the principal disclosed action is the appointment of a new director to the board, making this an exec_appointment event. The appointment is material as it expands the board from six to seven directors and brings an experienced advertising industry executive with deep AI expertise to the company's governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-13
Item 5.02
Michael P. Dickerson was appointed as Interim Chief Financial Officer on July 11, 2026, following Joseph Visconti's resignation from that role. Dickerson's consulting agreement was amended to provide equity grants of 3,970 RSUs and contingent cash payments tied to the merger agreement.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-13
Item 5.02
The filing discloses the appointment of two new directors—Robert Iannone, M.D., M.S.C.E. as a Class I director and Flavia Borellini, Ph.D. as a Class II director—to fill newly-created board vacancies following an increase in authorized board size from seven to nine members. Dr. Borellini was also appointed chairperson of the R&D Committee. This is a clear executive appointment event material to investors assessing board composition and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-13
Item 8.01
Russell Rosa was appointed Chief Revenue Officer of N-able effective immediately, with responsibility for the global sales organization, channel and partner ecosystem, support, and sales operations.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-13
Item 5.02
Klaviyo appointed Erica Smith as Chief Financial Officer effective September 1, 2026, succeeding Amanda Whalen. Smith's compensation package includes a base salary of $550,000, 50% bonus target, $15M RSU grant, and $3M PSU grant.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-13
Item 5.02
Amechi Nwachuku was appointed as Chief Operating Officer effective July 13, 2026, a senior executive position. While the disclosure includes compensatory details (base salary of $445,000, 45% target bonus, 800,000 stock options, and severance arrangements), the principal disclosed action is the appointment of a named executive to a C-suite role. This is material to investors as it signals a significant leadership change at the company.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-13
Item 5.02
The Board appointed Steven Bandrowczak, a former CEO of Xerox with extensive senior leadership experience, to serve as a director effective July 13, 2026, and as a member of the audit committee. This is a clear executive appointment of a director to the Board, which is material to investors as it affects governance composition and audit oversight.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-13
Item 5.02
The filing discloses both a board resignation (Bill Beargie on July 7, 2026) and a board appointment (Rick Keyes on July 8, 2026). While both events are present, the substantive disclosure centers on the appointment of Rick Keyes as an independent director with detailed background on his qualifications, including his role as President and CEO of Meijer, Inc. since 2017, and his service on other public company boards. The appointment is the principal forward-looking action and is material to investors assessing board composition and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-10
Item 5.02
O'Reilly appointed Colin Yankee as Executive Vice President and Chief Supply Chain Officer, effective July 13, 2026. While the disclosure includes compensatory details (base salary of $700,000, performance incentive target of 85%, stock option awards totaling $500,000 grant-date fair value plus annual grants), the principal disclosed action is the appointment of a named executive officer to a senior leadership position. This is a material executive appointment that would affect investor assessment of the company's leadership and operational strategy.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-10
Item 5.02
Four independent directors—Garrett Curran, Alberto Alsina Gonzalez, Matthew Murphy, and Marc Spiegel—were appointed to the board of directors on July 9, 2026 in connection with the IPO, with assignments to the Audit and Compensation committees. This material governance event establishes the company's independent board oversight structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-07-10
Item 5.02
The filing discloses both the resignation of two directors (William M. Goodyear and Mark McGowan) and the appointment of Maria Veltre to the Board, effective immediately on July 10, 2026. While both events are disclosed, the principal action emphasized in the Item 5.02 structure and press release is the appointment of Veltre as a new director, making this an exec_appointment event. The departures are characterized as planned and non-contentious, and the Board reduction is a routine governance adjustment. Veltre's appointment to the Board of a NYSE-listed company is material to investors.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-07-10
The 6-K discloses the appointment of Wesley Chu as an independent director, chairman of the compensation committee, and member of the audit and nominating committees, effective July 10, 2026. While the filing also mentions the concurrent resignation of Qi Ding, the principal disclosed action is Chu's appointment to the Board with specific committee assignments and compensation. The appointment is material as it affects board composition and governance structure, particularly in the context of the Company's stated intention to increase U.S.-based board representation.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-10
The 6-K discloses the election of Mr. Alessandro de Castro Melo to the position of Chief Engineering, Technology and Innovation Officer by the Board of Directors on July 10, 2026. This is a material executive appointment to a named officer position, approved by the Board following recommendation by the People and Organization Committee, with a term extending to 2028.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-10
Item 7.01
The filing discloses the appointment of Jeff Hopmayer to MDWerks' Board of Directors, effective June 26, 2026. The press release (Exhibit 99.1) emphasizes Hopmayer's appointment as a pivotal addition to the board during a critical commercial inflection point, highlighting his experience in building and scaling businesses and his role in corporate strategy, partnerships, and M&A. This is a clear executive appointment event, material to investors assessing the company's leadership and strategic direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-10
Item 5.02
The disclosure centers on the appointment of Matt Levine as Chief Legal Officer effective July 27, 2026, with detailed background on his prior roles at Clear Secure and Success Academy. While Erin Abrams's departure is also mentioned, the principal action disclosed is the appointment of a new CLO to fill this officer-level position. The appointment of a C-suite executive is material to investors assessing the company's leadership and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-10
Item 5.02
The filing discloses the appointment of Joshua Chien as an independent director of the Board, effective July 8, 2026, upon recommendation from the Nominating and Corporate Governance Committee. While the Item 5.02 section also mentions compensatory arrangements (annual cash retainer of $60,000 and restricted share unit award of $170,000), the principal disclosed action is the appointment of a director to the Board. This is material as it affects the composition and governance of the company's leadership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-10
Item 5.02
The filing discloses the appointment of two independent directors, Vivek Mohindra and Eiso Kant, to the Board of Directors of Axon Enterprise effective July 8, 2026, along with their committee assignments. While the disclosure also includes compensatory arrangements (RSU awards and cash retainers), the principal disclosed action centers on the appointment of these individuals to the Board and their committee roles, making exec_appointment the most salient classification. The material nature is clear given the addition of senior leadership to the Board.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-07-10
EX-99.1
The press release announces the appointment of Carl von Halem as Interim Chief Financial Officer of VERAXA Biotech AG, succeeding Torsten Bürgermeister. While the disclosure also references Bürgermeister's departure, the principal disclosed action is the appointment of a named executive to a C-suite role. The appointment of a CFO is material to investors as it affects the company's financial leadership and operational continuity, particularly given the company's recent NASDAQ listing and growth phase.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-10
Item 5.02
Neil Adler was appointed as Chief Financial Officer effective July 9, 2026, with an annual base salary of $200,000. The appointment follows the non-renewal of the employment agreement of departing CFO Neelam Patel, effective September 16, 2026.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-09
Item 5.02
The filing discloses the appointment of three officers to SoCalGas: Karen L. Sedgwick as CEO and President (effective Q3 2026), Ross W. Turrini as Chief Operating Officer (effective August 10, 2026), and Elvia Lima Ortiz as Vice President, Chief Accounting Officer and Controller (effective July 10, 2026). While the section also includes a departure (Sara P. Mijares resigning as Chief Accounting Officer) and compensation details for the new appointees, the principal disclosed actions center on the three executive appointments, particularly the CEO appointment, which is material to investors assessing leadership and strategic direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-09
Item 5.02
Frank Scognamiglio was appointed as Corporate Vice President, Chief Accounting Officer, effective July 9, 2026, succeeding Christopher Caridi as the Company's principal accounting officer. While the disclosure includes compensatory details (base salary of $340,000, target bonus of 40%, and RSU grant of $100,000), the principal disclosed action is the appointment of an officer to a key financial leadership role. The appointment of a principal accounting officer is material to investors' assessment of financial reporting governance and internal controls.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-09
Item 5.02
Central Plains Bancshares, Inc. appointed two individuals, Dannel R. Garness and Francis Younes, to the Boards of Directors of both Central Plains Bancshares, Inc. and Home Federal Savings and Loan Association of Grand Island on July 7, 2026. The appointment of Francis Younes followed an interview process initiated by activist shareholder pressure from the Stilwell Group.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-09
Item 5.02
The company appointed Giorgio Matteo Tarditi as President and Chief Operating Officer, Louis Martin as Chief Commercial Officer, and Alfredo Luchini as Chief Financial Officer, effective August 3–10, 2026, representing a significant restructuring of senior leadership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-09
Item 5.02
The filing discloses the Board's appointment of Justin C. Bird as Executive Vice President and Chief Financial Officer of Sempra, effective on or around the closing of the planned sale of Sempra Infrastructure Partners equity (Q3 2026). While the filing also mentions Karen L. Sedgwick's concurrent appointment as CEO and President of Southern California Gas Company, the principal disclosed action centers on Bird's appointment to the CFO role—a material executive position change at the parent company level. The appointment of a CFO with over two decades of leadership experience at Sempra is material to investors assessing the registrant's governance and financial leadership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-09
Item 5.02
Kristina Campbell was appointed to the Board of Directors effective July 6, 2026, as an independent director and designated as Chair of the Audit Committee. Campbell brings extensive fintech and digital asset experience from her roles as CFO at Ripple Labs, PayNearMe, and Wrapbook, and is designated as an Audit Committee Financial Expert.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-09
Item 5.02
The filing discloses the appointment of Nancy Bowman, M.D., Ph.D., as Chief Regulatory Officer effective August 3, 2026, succeeding William Turner. While Turner's transition to Special Advisor represents a departure from his CRO role, the principal disclosed action centers on the appointment of a new CRO—a material executive officer position at a therapeutic company where regulatory affairs are critical to operations and strategy.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 94%
filed 2026-07-09
Item 5.02
FibroBiologics appointed Kathleen Rubins, Ph.D., a retired NASA astronaut and microbiologist, as a Class III director effective July 8, 2026, with assignment to the Audit, Compensation, and Governance committees. Dr. Rubins brings distinguished scientific credentials and has served on the company's Scientific Advisory Board since 2022.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-09
Item 5.02
Paycom appointed two directors to its board effective July 8, 2026: Craig E. Boelte, former CFO (retired February 2025), and William Kerber, former CIO (departed 2017). Both individuals bring substantial company history and expertise to the board.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-09
EX-99.1
The press release announces the appointment of Ralph (Cody) Kittle to Telesat's Board of Directors as a nominee of MHR Fund Management LLC, succeeding Michael Targoff. This is a discrete governance event involving the appointment of a director to the board. While the release also acknowledges Targoff's departure after 19 years, the principal disclosed action is Kittle's appointment to the board, making this an exec_appointment event. Board composition changes at public companies are material to investors assessing governance and oversight.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-09
Item 5.02
The disclosure centers on the appointment of Derek Rush as a director and member of the audit committee on July 2, 2026, increasing the Board to seven members. While the section also mentions an indemnification agreement, the principal disclosed action is the appointment of a person to a board role. This is material to investors as it affects board composition and governance structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-09
Item 5.02
On July 7, 2026, Bronwyn Barnes, Quinton Hennigh, Hugh Callaghan, and Michael Porter were appointed to the board of directors, with Barnes serving as Chairwoman and Porter chairing both the Audit and Compensation Committees.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 85%
filed 2026-07-09
The 6-K discloses the appointment of two new independent directors effective July 9, 2026: Mr. King Fui Lee as an independent director and Audit Committee Chairman, and Mr. Ke Zhang as an independent director. While the filing also mentions the departure of two prior independent directors (Ms. Jie Jiao and Mr. Jingchuan Li), the principal disclosed action is the appointment of new board members with detailed biographical information, making this an exec_appointment event. Board composition changes affecting audit oversight are material to investors.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-09
Item 5.02
The filing discloses both a departure (Cory Nickel's termination as Senior Vice President and General Manager) and an appointment (John Jamieson's appointment to the same role, effective immediately on July 7, 2026). While both events occurred, the principal disclosed action centers on the appointment of Jamieson to a senior operational role with a salary increase from $193,000 to $205,000. The detailed biographical information and Board approval of compensation changes emphasize the appointment as the primary event. This is material as it involves a change in senior management responsible for operations.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-09
EX-99.1
The exhibit announces the appointment of Brian Hartzband as President of U.S. Operations, a named executive role. The disclosure emphasizes his responsibility for leading U.S. growth strategy, commercial operations, and market expansion—a material operational leadership position. The appointment is presented as a strategic milestone supporting the company's North American expansion and long-term growth execution.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-09
Item 7.01
The filing discloses the Board's appointment of Alisa Bowen as Chief Executive Officer of FuboTV, effective July 10, 2026, succeeding co-founder David Gandler. While Gandler's departure is also mentioned, the principal disclosed action centers on the appointment of a new CEO—a veteran media executive with extensive experience at Disney, News Corporation, and other major media organizations. This is a material executive leadership transition at a public company.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-07-09
Item 5.02
Haiyan Song was appointed as a new Class III director effective July 9, 2026, bringing cybersecurity and software expertise to strengthen the Board's capabilities. The appointment was accompanied by related board transitions including Greg Nixon's resignation as preferred stock director and Nathaniel Fick's transition from Class III to preferred stock director.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-09
GSK announced the appointment of Roy Jakobs as a Non-Executive Director effective 13 July 2026. The disclosure details his background as CEO of Royal Philips, his independence status, compensation terms (£122,258 annual fee), and share ownership requirements. This is a clear executive appointment to the Board, material to investors assessing governance and leadership composition.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-09
Item 5.02
David Kratochvil was appointed as Chief Executive Officer on July 2, 2026, following the resignation of Mike Schmidt. The appointment includes a new employment agreement with a base salary of $180,000 and 100,000 stock units.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-09
Item 5.02
Enovix announced the appointment of Dr. Michael Vyvoda as Chief Operating Officer, effective July 29, 2026. The disclosure details his background, compensation package ($440,000 base salary plus 60% bonus target and $4.1 million in RSUs), and severance terms. While the filing includes compensatory arrangements, the principal disclosed action is the appointment of a named executive officer to a C-suite role, making exec_appointment the most salient classification.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 72%
filed 2026-07-09
Item 5.02
The disclosure centers on two executive transitions: David Pirman's promotion to Executive Vice President and Head of Discovery (a clear appointment to a senior role), and Bruce Car's transition from Chief Scientific Officer to Chief Innovation Officer (a role change with reduced compensation). While Car's departure from the CSO role is mentioned, the filing emphasizes the new appointments and organizational restructuring rather than focusing on departures. The promotion of Pirman to lead the internal drug-discovery organization and Car's continued service as an executive officer in a newly created role constitute material executive appointments that would affect investor assessment of the company's scientific leadership structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-08
Item 5.02
Matthew Toboroff was appointed to the Board of Directors effective July 1, 2026, to fill a vacancy created by the death of Thom Kidrin. The disclosure centers on the appointment action itself. While the filing also mentions a related departure (Kidrin's passing), the principal disclosed action is Toboroff taking a director role. The appointment is material as it affects board composition and involves a related-party relationship (Toboroff's father is the Interim CEO and a Director).
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-07-08
Item 5.02
Brad Martin was appointed as Executive Vice President and Chief Information Officer, a named executive officer role at the financial institution. The appointment was made in advance of Tammy Plummer's retirement to ensure a smooth leadership transition.
View raw filing on EDGAR →